neuradiab
Small moleculeexperimental
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 2008 (NCT00615186)
Timeline
Indications
Mechanism of action
- TenascinRadiodepletion
TNC radiodepletion
Chemistry & pharmacology
- Payload
- 131-iodine
Oral
No
Parenteral
No
Topical
No
Also known as
- neuradiab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00906516 | Phase 2 | May 1, 2009 | Bradmer Pharmaceuticals Inc., Duke University |
| NCT00615186 | Phase 3 | Jun 1, 2008 | Bradmer Pharmaceuticals Inc., Cedars-Sinai Medical Center, Cornell University, Duke University, University of Nebraska, University of South Florida |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bradmer Pharmaceuticals Inc. | For profit | 2 | 2 | 2 | 2008 |
| Duke University | Academic/Hospital | 2 | 0 | 2 | 2008 |
| Cedars-Sinai Medical Center | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Nebraska | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of South Florida | Academic/Hospital | 1 | 0 | 1 | 2008 |
6 organizations
Page 1 / 1